Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

Avelumab, a human anti–programmed death ligand 1 immunoglobulin G1 antibody, has shown efficacy and manageable safety in multiple tumors. A two‐compartment population pharmacokinetic model for avelumab incorporating intrinsic and extrinsic covariates and time‐varying clearance (CL) was identified ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkins, Justin J., Brockhaus, Brigitte, Dai, Haiqing, Vugmeyster, Yulia, White, Joleen T., Brar, Satjit, Bello, Carlo L., Neuteboom, Berend, Wade, Janet R., Girard, Pascal, Khandelwal, Akash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617853/
https://www.ncbi.nlm.nih.gov/pubmed/30980481
http://dx.doi.org/10.1002/psp4.12406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617853/
https://www.ncbi.nlm.nih.gov/pubmed/30980481
http://dx.doi.org/10.1002/psp4.12406

Ejemplares similares